Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.